FGP
NBIX icon

Freestone Grove Partners’s Neurocrine Biosciences NBIX Stock Holding History

Freestone Grove Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,997
Closed -$1.58M – 1223
2026
Q1 		$1.58M Sell
11,997
-128,532
-91% -$17.1M 0.01% 401
2025
Q4 		$19.9M Buy
140,529
+8,191
+6% +$1.19M 0.14% 210
2025
Q3 		$18.6M Sell
132,338
-35,795
-21% -$4.85M 0.14% 224
2025
Q2 		$21.1M Buy
168,133
+162,924
+3,128% +$18.7M 0.16% 193
2025
Q1 		$576K Buy
+5,209
New +$660K 0.01% 395

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Freestone Grove Partners's NBIX Position: Q2 2026 in Review

Freestone Grove Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 11,997 shares — an estimated $1.58M sold.

Freestone Grove Partners first reported a position in NBIX in Q1 2025 and held it in 5 quarters. The position peaked at $21.1M in Q2 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Freestone Grove Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 11,997 Neurocrine Biosciences shares in Q2 2026, an estimated $1.58M.
  • Freestone Grove Partners first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 5 quarters.
  • Freestone Grove Partners's Neurocrine Biosciences position peaked at $21.1M in Q2 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.